Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Metronomic Eribulin (Halaven) in Pretreated Metastatic Breast Cancer (MBC)

NCT01908101 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT01908101
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01908101 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Metronomic Eribulin (Halaven) in Pretreated Metastatic Breast Cancer (MBC)
Lead sponsor
University of Washington
Phase
Phase 2
Overall status
Completed
Start date
January 8, 2014
Completion date
May 4, 2019
Enrollment
86 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent breast carcinoma, stage iv breast cancer